RSV prophylaxis guideline changes and outcomes in children with congenital heart disease

ObjectiveThe aim of this study was to compare inpatient outcomes and costs for children with respiratory syncytial virus and congenital heart disease before and after the change in management guidelines for respiratory syncytial virus prophylaxis.DesignHospital discharge data from the Vizient (formerly University HealthSystem Consortium) were queried from October 2012 to June 2014 (Era 1) and July 2014 to April 2016 (Era 2) for patients aged <24 months with an any International Classification of Disease (ICD)‐9 or ICD‐10 code for congenital heart disease (745‐747.49, Q20.0‐Q26.4) and a primary or secondary admitting diagnosis of respiratory syncytial virus infection (079.6, J20.5), acute bronchiolitis due to respiratory syncytial virus (466.11, J21.0) or respiratory syncytial virus pneumonia (480.1, J12.1).SettingThis study is a review of a national administrative discharge database.Patients: Respiratory syncytial virus admissions were identified in 1269 patients aged